The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Open accessPublished version of a preprint
Abstract
The phosphoinositide 3-kinase (PI3K)/AKT and RAF/MEK/ERK signaling pathways are activated in a wide range of human cancers. In many cases, concomitant inhibition of both pathways is necessary to block proliferation and induce cell death and tumor shrinkage. Several feedback systems have been described in which inhibition of one intracellular pathway leads to activation of a parallel signaling pathway, thereby decreasing the effectiveness of single-agent targeted therapies. In this study, we describe a feedback mechanism in which MEK inhibition leads to activation of PI3K/AKT signaling in EGFR and HER2-driven cancers. We found that MEK inhibitor–induced activation of PI3K/AKT resulted from hyperactivation of ERBB3 as a result of the loss of an inhibitory threonine phosphorylation in the conserved juxtamembrane domains of EGFR and HER2. Mutation of this amino acid led to increased ERBB receptor activation and upregulation of the ERBB3/PI3K/AKT signaling pathway, which was no longer responsive to MEK inhibition. Taken together, these results elucidate an important, dominant feedback network regulating central oncogenic pathways in human cancer. Cancer Res; 72(13); 3228–37. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inhibition of either PI3K/mTOR or ERK signaling often relieves feedback inhibition of the other and causes its activation46,47.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [47]
In the citing paper
“In NSCLCs and CRCs, KRASG12C inhibition leads to an accumulation of activated upstream EGFR and/or other ERBB family members, which facilitates escape from KRASG12C-inhibitor monotherapy110,121–124.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600
Self-citationmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Self-citationPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
Self-citationAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Sun, S., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 800
Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Jura, N., Endres, N., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 609
Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D. J., Brandhuber, B. J., Gross, S. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578
Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzmán, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 541
Engelman, J. A., Janne, P. A., Mermel, C. H., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K. M., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 500
Self-citationHoeflich, K. P., O'Brien, C. L., Boyd, Z. S., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H. M., Punnoose, E. A., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 474
Targeting the RAF–MEK–ERK pathway in cancer therapy
Montagut, C. O., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 466
Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 457
Self-citationCharacterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
Dibble, C. C., Asara, J. M., & Manning, B. D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00735-09 · Cited by 433
Self-citationMirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D. R., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 387
Zheng, B., Jeong, J. H., Asara, J. M., Yuan, Y.-Y., Granter, S. R., Chin, L., & Cantley, L. C. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.026 · Cited by 364
Self-citationChakrabarty, A., Sanchez, V. M., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 353
Self-citationThe Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
Brewer, M. R., Choi, S. H., Alvarado, D., Moravcevic, K., Pozzi, A., Lemmon, M. A., & Carpenter, G. F. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.034 · Cited by 323
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Faber, A. C., Li, D., Song, Y., Liang, M.-C., Yeap, B. Y., Bronson, R. T., Lifshits, E., Chen, Z., Maira, S.-M., García-Echeverría, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 319
Self-citationOno, M., Hirata, A., Kometani, T., Miyagawa, M., Ueda, S.-I., Kinoshita, H., Fujii, T., & Kuwano, M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.465.3.4 · Cited by 305
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. E. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 292
Self-citationTargeting HER proteins in cancer therapy and the role of the non-target HER3
Hsieh, A. C., & Moasser, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603910 · Cited by 267
Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210
Self-citationNorthwood, I. C., Gonzalez, F. A., Wartmann, M., Raden, D. L., & Davis, R. J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98612-6 · Cited by 209
Takishima, K., Griswold‐Prenner, I., Ingebritsen, T. S., & Rosner, M. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2520 · Cited by 159
Yu, C. F., Liu, Z., & Cantley, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200732200 · Cited by 156
An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels
Diamonti, A. J., Guy, P. M., Ivanof, C., Wong, K., Sweeney, C. A., & Carraway, K. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052709799 · Cited by 126
Li, X., Huang, Y., Jiang, J., & Frank, S. J. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.08.006 · Cited by 111
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
Carracedo, A., Baselga, J. M., & Pandolfi, P. P. (2008) · Cell Cycle · doi:10.4161/cc.7.24.7244 · Cited by 84
Yoon, Y., Kim, H., Han, S., Hur, H.-S., Oh, D. Y., Im, S., Bang, Y., & Kim, T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0300 · Cited by 73
Faber, A. C., Dufort, F. J., Blair, D., Wagner, D. J., Roberts, M. F., & Chiles, T. C. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.009 · Cited by 68
Identification of Major ERK-Related Phosphorylation Sites in Gab1
Lehr, S., Kotzka, J., Avci, H., Sickmann, A., Meyer, H. E., Herkner, A., & Müller‐Wieland, D. (2004) · Biochemistry · doi:10.1021/bi049753e · Cited by 61
Modeling oncogene addiction using RNA interference
Rothenberg, S. M., Engelman, J. A., Le, S., Riese, D. J., Haber, D. A., & Settleman, J. E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803217105 · Cited by 48
Self-citationE3 ubiquitin ligases in ErbB receptor quantity control
Carraway, K. L. (2010) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2010.09.006 · Cited by 47
Activated ERK2 Interacts with and Phosphorylates the Docking Protein GAB1
Roshan, B., Kjelsberg, C., Spokes, K., Eldred, A., Crovello, C. S., & Cantley, L. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36362 · Cited by 36
The Juxtamembrane Region of EGFR Takes Center Stage
Hubbard, S. R. (2009) · Cell · doi:10.1016/j.cell.2009.06.008 · Cited by 30
Cited by
Sorted by citations
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Self-citationA Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C. I., Drulă, R., Gulei, D., Ráduly, L., Alexandru Vasile, R. U. S. U., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 940
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Metadata
- Authors
- Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Engelman, Jeffrey A.
- ORCID
- Venue
- Cancer Research
- Published
- 2012-07-01
- Volume
- 72
- Issue
- 13
- Pages
- 3228-3237
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3515079
- OpenAlex
- W2105437003
- Cited by
- 368
- References
- 37
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 22 · 2023: 30 · 2022: 32 · 2021: 21 · 2020: 27 · 2019: 25 · 2018: 27 · 2017: 30 · 2016: 36 · 2015: 25 · 2014: 30 · 2013: 18 · 2012: 3
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50 CA98131, R01 CA80195, P50CA127003, R01CA166480, U01CA141457, R01CA080195, R01CA140594, P50CA090578, K08CA120060, P50CA098131, P01CA120964, R01CA137008, P30CA006516)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- MEK inhibition, PI3K/Akt signaling, HER3, ErbB receptors, EGFR, HER2, negative feedback loop, Raf/MEK/ERK pathway, drug resistance, cancer pathways
- MeSH terms
- Cell Line, Enzyme Activation, Feedback, Flow Cytometry, Phosphatidylinositol 3-Kinases, Reverse Transcriptase Polymerase Chain Reaction, Receptor Protein-Tyrosine Kinases, Mitogen-Activated Protein Kinase Kinases, Proto-Oncogene Proteins c-akt, Tandem Mass Spectrometry, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
